Important molecular genetic markers of colorectal cancer

Oncotarget

Volumn 7, Issue 33, 2016, Pages 53959-53983

  Kudryavtseva, Anna V ^a,b   Lipatova, Anastasia V ^a   Zaretsky, Andrew R ^c   Moskalev, Alexey A ^a   Fedorova, Maria S ^a,b   Rasskazova, Anastasiya S ^a   Shibukhova, Galina A ^b   Snezhkina, Anastasiya V ^a   Kaprin, Andrey D ^b   Alekseev, Boris Y ^b   Dmitriev, Alexey A ^a   Krasnov, George S ^a,d  

^a ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

^b The Ministry of Healthcare of Russia   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^d INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

Author keywords

Chromosomal instability; Colorectal cancer; cpG island methylator phenotype; Microsatellite instability; Molecular markers

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; DNA METHYLTRANSFERASE 3B; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUCURONOSYLTRANSFERASE 1A1; PROTEIN P53; TUMOR MARKER;

BRAF GENE; CANCER CLASSIFICATION; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CPG ISLAND; EXCISION REPAIR; GENE FREQUENCY; GENE MUTATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE N RAS; PHENOTYPE; PIK3CA GENE; REVIEW; SIGNAL TRANSDUCTION; STRUCTURAL GENE; COLORECTAL TUMOR; GENETICS;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; GENETIC MARKERS; HUMANS;

EID: 84982295506     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9796     Document Type: Review

References (248)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65:87-108.
2. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S, Davies SR, Wang S, Wang P, Kinsinger CR, Rivers RC, Rodriguez H, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014; 513:382-387.
3. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
4. Pino MS and Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010; 138:2059-2072.
5. Leggett B and Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010; 138:2088-2100.
6. Boland CR and Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010; 138:2073-2087 e2073.
7. Lengauer C, Kinzler KW and Vogelstein B. Genetic instabilities in human cancers. Nature. 1998; 396:643-649.
8. Schneikert J and Behrens J. The canonical Wnt signalling pathway and its APC partner in colon cancer development. Gut. 2007; 56:417-425.
9. Miyaki M, Konishi M, Kikuchi-Yanoshita R, Enomoto M, Igari T, Tanaka K, Muraoka M, Takahashi H, Amada Y, Fukayama M and et al. Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer research. 1994; 54:3011-3020.
10. Najdi R, Holcombe RF and Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. Journal of carcinogenesis. 2011; 10:5.
11. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, Glickman JN, Niwa-Kawakita M, Sweet-Cordero A, Sebolt-Leopold J, Shannon KM, Settleman J, Giovannini M and Jacks T. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nature genetics. 2008; 40:600-608.
12. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Gonzalez S, Tarafa G, Sidransky D, Meltzer SJ, Baylin SB and Herman JG. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer research. 2000; 60:4366-4371.
13. Abdel-Rahman WM, Lotsari-Salomaa JE, Kaur S, Niskakoski A, Knuutila S, Jarvinen H, Mecklin JP and Peltomaki P. The Role of Chromosomal Instability and Epigenetics in Colorectal Cancers Lacking beta-Catenin/ TCF Regulated Transcription. Gastroenterology research and practice. 2016; 2016:6089658.
14. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH and Clevers H. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nature cell biology. 2001; 3:433-438.
15. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK and Nathke IS. A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nature cell biology. 2001; 3:429-432.
16. Aoki K, Aoki M, Sugai M, Harada N, Miyoshi H, Tsukamoto T, Mizoshita T, Tatematsu M, Seno H, Chiba T, Oshima M, Hsieh CL and Taketo MM. Chromosomal instability by beta-catenin/TCF transcription in APC or beta-catenin mutant cells. Oncogene. 2007; 26:3511-3520.
17. Alberici P and Fodde R. The role of the APC tumor suppressor in chromosomal instability. Genome dynamics. 2006; 1:149-170.
18. Herzog F, Primorac I, Dube P, Lenart P, Sander B, Mechtler K, Stark H and Peters JM. Structure of the anaphasepromoting complex/cyclosome interacting with a mitotic checkpoint complex. Science. 2009; 323:1477-1481.
19. Zhao Y, Ando K, Oki E, Ikawa-Yoshida A, Ida S, Kimura Y, Saeki H, Kitao H, Morita M and Maehara Y. Aberrations of BUBR1 and TP53 gene mutually associated with chromosomal instability in human colorectal cancer. Anticancer research. 2014; 34:5421-5427.
20. Overlack K, Primorac I, Vleugel M, Krenn V, Maffini S, Hoffmann I, Kops GJ and Musacchio A. A molecular basis for the differential roles of Bub1 and BubR1 in the spindle assembly checkpoint. eLife. 2015; 4:e05269.
21. Cahill DP, Lengauer C, Yu J, Riggins GJ, Willson JK, Markowitz SD, Kinzler KW and Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature. 1998; 392:300-303.
22. Bardelli A, Cahill DP, Lederer G, Speicher MR, Kinzler KW, Vogelstein B and Lengauer C. Carcinogen-specific induction of genetic instability. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:5770-5775.
23. Ganem NJ, Godinho SA and Pellman D. A mechanism linking extra centrosomes to chromosomal instability. Nature. 2009; 460:278-282.
24. Basto R, Brunk K, Vinadogrova T, Peel N, Franz A, Khodjakov A and Raff JW. Centrosome amplification can initiate tumorigenesis in flies. Cell. 2008; 133:1032-1042.
25. Lukasiewicz KB and Lingle WL. Aurora A, centrosome structure, and the centrosome cycle. Environmental and molecular mutagenesis. 2009; 50:602-619.
26. Zou J, Zhang D, Qin G, Chen X, Wang H and Zhang D. BRCA1 and FancJ cooperatively promote interstrand crosslinker induced centrosome amplification through the activation of polo-like kinase 1. Cell cycle. 2014; 13:3685-3697.
27. Ewart-Toland A, Briassouli P, de Koning JP, Mao JH, Yuan J, Chan F, MacCarthy-Morrogh L, Ponder BA, Nagase H, Burn J, Ball S, Almeida M, Linardopoulos S and Balmain A. Identification of Stk6/STK15 as a candidate lowpenetrance tumor-susceptibility gene in mouse and human. Nature genetics. 2003; 34:403-412.
28. Anand S, Penrhyn-Lowe S and Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer cell. 2003; 3:51-62.
29. Takahashi Y, Sheridan P, Niida A, Sawada G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y, Hase K, Kusunoki M, Kudo S, Watanabe M, Yamada K, Sugihara K, et al. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC. Annals of oncology. 2015; 26:935-942.
30. Baran V, Solc P, Kovarikova V, Rehak P and Sutovsky P. Polo-like kinase 1 is essential for the first mitotic division in the mouse embryo. Molecular reproduction and development. 2013; 80:522-534.
31. Archambault V and Carmena M. Polo-like kinase-activating kinases: Aurora A, Aurora B and what else? Cell cycle. 2012; 11:1490-1495.
32. Takahashi T, Sano B, Nagata T, Kato H, Sugiyama Y, Kunieda K, Kimura M, Okano Y and Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer science. 2003; 94:148-152.
33. Han DP, Zhu QL, Cui JT, Wang PX, Qu S, Cao QF, Zong YP, Feng B, Zheng MH and Lu AG. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Medical science monitor. 2012; 18:BR237-246.
34. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS and Ogino S. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia. 2009; 11:418-425.
35. Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC and Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in pharmacology. 2015; 6:120.
36. Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ and Deng HX. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. Cancer biotherapy & radiopharmaceuticals. 2011; 26:427-436.
37. Goktas S, Yildirim M, Suren D, Alikanoglu AS, Dilli UD, Bulbuller N, Sezer C and Yildiz M. Prognostic role of Aurora-A expression in metastatic colorectal cancer patients. Journal of BUON. 2014; 19:686-691.
38. Goos JA, Coupe VM, Diosdado B, Delis-Van Diemen PM, Karga C, Belien JA, Carvalho B, van den Tol MP, Verheul HM, Geldof AA, Meijer GA, Hoekstra OS, Fijneman RJ and DeCoDe PETG. Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. British journal of cancer. 2013; 109:2445-2452.
39. Bunting SF and Nussenzweig A. End-joining, translocations and cancer. Nature reviews Cancer. 2013; 13:443-454.
40. Matsui A, Ihara T, Suda H, Mikami H and Semba K. Gene amplification: mechanisms and involvement in cancer. Biomolecular concepts. 2013; 4:567-582.
41. Rudolph KL, Millard M, Bosenberg MW and DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nature genetics. 2001; 28:155-159.
42. Baichoo E and Boardman LA. Toward a molecular classification of colorectal cancer: the role of telomere length. Frontiers in oncology. 2014; 4:158.
43. Nakamura K, Furugori E, Esaki Y, Arai T, Sawabe M, Okayasu I, Fujiwara M, Kammori M, Mafune K, Kato M, Oshimura M, Sasajima K and Takubo K. Correlation of telomere lengths in normal and cancers tissue in the large bowel. Cancer letters. 2000; 158:179-184.
44. Engelhardt M, Drullinsky P, Guillem J and Moore MA. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clinical cancer research. 1997; 3:1931-1941.
45. Chadeneau C, Hay K, Hirte HW, Gallinger S and Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer research. 1995; 55:2533-2536.
46. Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R and Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. British journal of cancer. 2015; 112:313-318.
47. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, Ulm K, Holzmann B, Nekarda H and Siewert JR. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. Journal of clinical oncology. 2004; 22:1807-1814.
48. Bassing CH, Suh H, Ferguson DO, Chua KF, Manis J, Eckersdorff M, Gleason M, Bronson R, Lee C and Alt FW. Histone H2AX: a dosage-dependent suppressor of oncogenic translocations and tumors. Cell. 2003; 114:359-370.
49. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, Eckhaus M, Ried T, Bonner WM and Nussenzweig A. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell. 2003; 114:371-383.
50. Kobayashi J, Tauchi H, Chen B, Burma S, Tashiro S, Matsuura S, Tanimoto K, Chen DJ and Komatsu K. Histone H2AX participates the DNA damage-induced ATM activation through interaction with NBS1. Biochemical and biophysical research communications. 2009; 380:752-757.
51. Bakhoum SF, Kabeche L, Murnane JP, Zaki BI and Compton DA. DNA-damage response during mitosis induces whole-chromosome missegregation. Cancer discovery. 2014; 4:1281-1289.
52. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Yamada H, Hayama T, Inoue E, Tamura J, Iinuma H, Akiyoshi T and Muto T. Chromosomal instability (CIN) phenotype, CIN high or CIN low, predicts survival for colorectal cancer. Journal of clinical oncology. 2012; 30:2256-2264.
53. Li LS, Kim NG, Kim SH, Park C, Kim H, Kang HJ, Koh KH, Kim SN, Kim WH, Kim NK and Kim H. Chromosomal imbalances in the colorectal carcinomas with microsatellite instability. The American journal of pathology. 2003; 163:1429-1436.
54. Yang G and Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. International journal of biological sciences. 2010; 6:1-8.
55. Woodford-Richens KL, Rowan AJ, Gorman P, Halford S, Bicknell DC, Wasan HS, Roylance RR, Bodmer WF and Tomlinson IP. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:9719-9723.
56. Tariq K and Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer biology & medicine. 2016; 13:120-135.
57. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG and Beauchamp RD. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Gastroenterology. 2012; 142:562-571 e562.
58. Kozak MM, von Eyben R, Pai J, Vossler SR, Limaye M, Jayachandran P, Anderson EM, Shaffer JL, Longacre T, Pai RK, Koong AC and Chang DT. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer. Journal of clinical pathology. 2015; 68:341-345.
59. Popat S, Zhao D, Chen Z, Pan H, Shao Y, Chandler I and Houlston RS. Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients. Anticancer research. 2007; 27:627-633.
60. Lebok P, Mittenzwei A, Kluth M, Ozden C, Taskin B, Hussein K, Moller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wolber L, Janicke F, Geist S, Paluchowski P, Wilke C, et al. 8p deletion is strongly linked to poor prognosis in breast cancer. Cancer biology & therapy. 2015; 16:1080-1087.
61. El Gammal AT, Bruchmann M, Zustin J, Isbarn H, Hellwinkel OJ, Kollermann J, Sauter G, Simon R, Wilczak W, Schwarz J, Bokemeyer C, Brummendorf TH, Izbicki JR, Yekebas E, Fisch M, Huland H, et al. Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer. Clinical cancer research. 2010; 16:56-64.
62. Sheffer M, Bacolod MD, Zuk O, Giardina SF, Pincas H, Barany F, Paty PB, Gerald WL, Notterman DA and Domany E. Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:7131-7136.
63. Donehower LA, Creighton CJ, Schultz N, Shinbrot E, Chang K, Gunaratne PH, Muzny D, Sander C, Hamilton SR, Gibbs RA and Wheeler D. MLH1-silenced and nonsilenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. The Journal of pathology. 2013; 229:99-110.
64. Briggs S and Tomlinson I. Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. The Journal of pathology. 2013; 230:148-153.
65. Silva FC, Valentin MD, Ferreira Fde O, Carraro DM and Rossi BM. Mismatch repair genes in Lynch syndrome: a review. Sao Paulo medical journal = Revista paulista de medicina. 2009; 127:46-51.
66. Ionov Y, Peinado MA, Malkhosyan S, Shibata D and Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993; 363:558-561.
67. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN and Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer research. 1998; 58:5248-5257.
68. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, Young JP, Barker MA, Jass JR, Hopper J, Gallinger S, Bapat B, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. Journal of clinical oncology. 2002; 20:1043-1048.
69. Thomas ML, Hewett PJ, Ruszkiewicz AR and Moore JW. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit. Asia-Pacific journal of clinical oncology. 2015; 11:343-351.
70. Carethers JM, Smith EJ, Behling CA, Nguyen L, Tajima A, Doctolero RT, Cabrera BL, Goel A, Arnold CA, Miyai K and Boland CR. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology. 2004; 126:394-401.
71. Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M and Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Annals of oncology. 2015; 26:126-132.
72. Collura A, Lagrange A, Svrcek M, Marisa L, Buhard O, Guilloux A, Wanherdrick K, Dorard C, Taieb A, Saget A, Loh M, Soong R, Zeps N, Platell C, Mews A, Iacopetta B, et al. Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil-based chemotherapy. Gastroenterology. 2014; 146:401-411 e401.
73. Tougeron D, Mouillet G, Trouilloud I, Lecomte T, Coriat R, Aparicio T, Des Guetz G, Lecaille C, Artru P, Sickersen G, Cauchin E, Sefrioui D, Boussaha T, Ferru A, Matysiak-Budnik T, Silvain C, et al. Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. Journal of the National Cancer Institute. 2016; 108.
74. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC, Jr., Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clinical chemistry. 2008; 54:e11-79.
75. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C and Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. European journal of cancer. 2007; 43:1348-1360.
76. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC, Jr. and Asco. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. Journal of clinical oncology. 2006; 24:5313-5327.
77. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP. CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96:8681-8686.
78. Bae JM, Kim JH and Kang GH. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype. Histology and histopathology. 2013; 28:585-595.
79. Ang PW, Loh M, Liem N, Lim PL, Grieu F, Vaithilingam A, Platell C, Yong WP, Iacopetta B and Soong R. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features. BMC cancer. 2010; 10:227.
80. Sideris M and Papagrigoriadis S. Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer research. 2014; 34:2061-2068.
81. Ahuja N, Mohan AL, Li Q, Stolker JM, Herman JG, Hamilton SR, Baylin SB and Issa JP. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer research. 1997; 57:3370-3374.
82. Weisenberger DJ, Siegmund KD, Campan M, Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D, Buchanan D, Koh H, Simms L, Barker M, Leggett B, Levine J, Kim M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature genetics. 2006; 38:787-793.
83. Toyota M, Ohe-Toyota M, Ahuja N and Issa JP. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97:710-715.
84. Hawkins N, Norrie M, Cheong K, Mokany E, Ku SL, Meagher A, O'Connor T and Ward R. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology. 2002; 122:1376-1387.
85. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK and Slattery ML. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology. 2005; 129:837-845.
86. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA and Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterology and hepatology from bed to bench. 2013; 6:120-128.
87. Barault L, Charon-Barra C, Jooste V, de la Vega MF, Martin L, Roignot P, Rat P, Bouvier AM, Laurent-Puig P, Faivre J, Chapusot C and Piard F. Hypermethylator phenotype in sporadic colon cancer: study on a populationbased series of 582 cases. Cancer research. 2008; 68:8541-8546.
88. Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M and Fuchs CS. Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. The Journal of molecular diagnostics. 2007; 9:305-314.
89. Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS and Ogino S. DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer. Clinical cancer research. 2009; 15:3663-3671.
90. Ibrahim AE, Arends MJ, Silva AL, Wyllie AH, Greger L, Ito Y, Vowler SL, Huang TH, Tavare S, Murrell A and Brenton JD. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression. Gut. 2011; 60:499-508.
91. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, Wolff RK and Slattery ML. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. Journal of the National Cancer Institute. 2006; 98:1731-1738.
92. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, Lynch CF, Anderson KE, French AJ, Haile RW, Harnack LJ, Potter JD, Slager SL, Smyrk TC, Thibodeau SN, Cerhan JR, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. Journal of the National Cancer Institute. 2010; 102:1012-1022.
93. van Engeland M, Weijenberg MP, Roemen GM, Brink M, de Bruine AP, Goldbohm RA, van den Brandt PA, Baylin SB, de Goeij AF and Herman JG. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer research. 2003; 63:3133-3137.
94. de Vogel S, Wouters KA, Gottschalk RW, van Schooten FJ, de Goeij AF, de Bruine AP, Goldbohm RA, van den Brandt PA, Weijenberg MP and van Engeland M. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer. Cancer epidemiology, biomarkers & prevention. 2009; 18:3086-3096.
95. Hazra A, Fuchs CS, Kawasaki T, Kirkner GJ, Hunter DJ and Ogino S. Germline polymorphisms in the one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer causes & control. 2010; 21:331-345.
96. Jia M, Gao X, Zhang Y, Hoffmeister M and Brenner H. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Clinical epigenetics. 2016; 8:25.
97. Dahlin AM, Palmqvist R, Henriksson ML, Jacobsson M, Eklof V, Rutegard J, Oberg A and Van Guelpen BR. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clinical cancer research. 2010; 16:1845-1855.
98. Ward RL, Cheong K, Ku SL, Meagher A, O'Connor T and Hawkins NJ. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability. Journal of clinical oncology. 2003; 21:3729-3736.
99. Bae JM, Kim MJ, Kim JH, Koh JM, Cho NY, Kim TY and Kang GH. Differential clinicopathological features in microsatellite instability-positive colorectal cancers depending on CIMP status. Virchows Archiv. 2011; 459:55-63.
100. Ahn JB, Chung WB, Maeda O, Shin SJ, Kim HS, Chung HC, Kim NK and Issa JP. DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer. 2011; 117:1847-1854.
101. Bae JM, Kim JH, Cho NY, Kim TY and Kang GH. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. British journal of cancer. 2013; 109:1004-1012.
102. Lee S, Cho NY, Choi M, Yoo EJ, Kim JH and Kang GH. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathology international. 2008; 58:104-113.
103. Issa JP. CpG island methylator phenotype in cancer. Nature reviews Cancer. 2004; 4:988-993.
104. Hughes LA, Khalid-de Bakker CA, Smits KM, van den Brandt PA, Jonkers D, Ahuja N, Herman JG, Weijenberg MP and van Engeland M. The CpG island methylator phenotype in colorectal cancer: progress and problems. Biochimica et biophysica acta. 2012; 1825:77-85.
105. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL and Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009; 58:90-96.
106. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, Hamilton SR, Laurent-Puig P, Gryfe R, Shepherd LE, Tu D, Redston M and Gallinger S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. The New England journal of medicine. 2003; 349:247-257.
107. Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Pinol V, Xicola RM, Bujanda L, Rene JM, Clofent J, Bessa X, Morillas JD, Nicolas-Perez D, Paya A, Alenda C, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut. 2006; 55:848-855.
108. Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K and Iacopetta B. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clinical cancer research. 2003; 9:2898-2903.
109. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Mahoney MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ and Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. Journal of clinical oncology. 2005; 23:9243-9249.
110. Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F and Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of clinical oncology. 2008; 26:2006-2012.
111. Alcindor T and Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Current oncology. 2011; 18:18-25.
112. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS and Wang WS. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer science. 2009; 100:278-283.
113. Woelfelschneider A, Popanda O, Lilla C, Linseisen J, Mayer C, Celebi O, Debus J, Bartsch H, Chang-Claude J and Schmezer P. A distinct ERCC1 haplotype is associated with mRNA expression levels in prostate cancer patients. Carcinogenesis. 2008; 29:1758-1764.
114. Park DJ, Zhang W, Stoehlmacher J, Tsao-Wei D, Groshen S, Gil J, Yun J, Sones E, Mallik N and Lenz HJ. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinumbased chemotherapy. Clinical advances in hematology & oncology: H&O. 2003; 1:162-166.
115. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, Catalano V, Ficarelli R, Maltese P, Bisonni R, Masi G, Schiavon G, Giordani P, Giustini L, Falcone A, Tonini G, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. Journal of clinical oncology. 2007; 25:1247-1254.
116. Ye F, Liu Z, Tan A, Liao M, Mo Z and Yang X. XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatinbased chemotherapy in colorectal cancer: a meta-analysis. Cancer chemotherapy and pharmacology. 2013; 71:733-740.
117. Qian YY, Liu XY, Wu Q, Song X, Chen XF, Liu YQ, Pei D, Shen LZ and Shu YQ. The ERCC1 C118T polymorphism predicts clinical outcomes of colorectal cancer patients receiving oxaliplatin-based chemotherapy: a meta-analysis based on 22 studies. Asian Pacific journal of cancer prevention. 2014; 15:8383-8390.
118. Milovic-Kovacevic M, Srdic-Rajic T, Radulovic S, Bjelogrlic S and Gavrilovic D. Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy. Journal of BUON. 2011; 16:708-714.
119. Leng XF, Chen MW, Xian L, Dai L, Ma GY and Li MH. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. Journal of experimental & clinical cancer research. 2012; 31:25.
120. Pospiech H and Syvaoja JE. DNA polymerase epsilon-more than a polymerase. TheScientificWorldJournal. 2003; 3:87-104.
121. Church DN, Stelloo E, Nout RA, Valtcheva N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ, Lambrechts D, Jurgenliemk-Schulz IM, Jobsen JJ, Smit VT, Creutzberg CL and Bosse T. Prognostic significance of POLE proofreading mutations in endometrial cancer. Journal of the National Cancer Institute. 2015; 107:402.
122. Billingsley CC, Cohn DE, Mutch DG, Stephens JA, Suarez AA and Goodfellow PJ. Polymerase varepsilon (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer. 2015; 121:386-394.
123. Stenzinger A, Pfarr N, Endris V, Penzel R, Jansen L, Wolf T, Herpel E, Warth A, Klauschen F, Kloor M, Roth W, Blaker H, Chang-Claude J, Brenner H, Hoffmeister M and Weichert W. Mutations in POLE and survival of colorectal cancer patients-link to disease stage and treatment. Cancer medicine. 2014; 3:1527-153.
124. Valle L, Hernandez-Illan E, Bellido F, Aiza G, Castillejo A, Castillejo MI, Navarro M, Segui N, Vargas G, Guarinos C, Juarez M, Sanjuan X, Iglesias S, Alenda C, Egoavil C, Segura A, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Human molecular genetics. 2014; 23:3506-3512.
125. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, Broderick P, Kemp Z, Spain SL, Guarino E, Salguero I, Sherborne A, Chubb D, Carvajal-Carmona LG, Ma Y, Kaur K, Dobbins S, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nature genetics. 2013; 45:136-144.
126. Yoshida R, Miyashita K, Inoue M, Shimamoto A, Yan Z, Egashira A, Oki E, Kakeji Y, Oda S and Maehara Y. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer. European journal of human genetics. 2011; 19:320-325.
127. Konstantinopoulos PA and Matulonis UA. POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. Cancer. 2015; 121:331-334.
128. Popanda O, Zheng C, Magdeburg JR, Buttner J, Flohr T, Hagmuller E and Thielmann HW. Mutation analysis of replicative genes encoding the large subunits of DNA polymerase alpha and replication factors A and C in human sporadic colorectal cancers. International journal of cancer Journal international du cancer. 2000; 86:318-324.
129. Deng Y, Wang L, Tan S, Kim GP, Dou R, Chen D, Cai Y, Fu X, Wang L, Zhu J and Wang J. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. Molecular oncology. 2015; 9:1341-1347.
130. Brudvik KW, Kopetz SE, Li L, Conrad C, Aloia TA and Vauthey JN. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. The British journal of surgery. 2015; 102:1175-1183.
131. Arrington AK, Heinrich EL, Lee W, Duldulao M, Patel S, Sanchez J, Garcia-Aguilar J and Kim J. Prognostic and predictive roles of KRAS mutation in colorectal cancer. International journal of molecular sciences. 2012; 13:12153-12168.
132. Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, Tzardi M, Mavroudis D, Georgoulias V and Voutsina A. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PloS one. 2014; 9:e104902.
133. Wennerberg K, Rossman KL and Der CJ. The Ras superfamily at a glance. Journal of cell science. 2005; 118:843-846.
134. Fernandez-Medarde A and Santos E. Ras in cancer and developmental diseases. Genes & cancer. 2011; 2:344-358. doi: 10.1177/1947601911411084.
135. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. British journal of cancer. 2009; 101:715-721.
136. Al-Shamsi HO, Alhazzani W and Wolff RA. Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers. Journal of gastrointestinal oncology. 2015; 6:314-321.
137. Boeckx N, Peeters M, Van Camp G, Pauwels P, Op de Beeck K and Deschoolmeester V. Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. Drugs. 2015; 75:1739-1756.
138. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. British journal of cancer. 2001; 85:692-696.
139. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Journal of clinical oncology. 2010; 28:466-474.
140. Yokota T. Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anticancer agents in medicinal chemistry. 2012; 12:163-171.
141. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S and Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta oncologica. 2014; 53:852-864.
142. Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F and Russo A. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer treatment reviews. 2010; 36 Suppl 3:S56-61.
143. Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, et al. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Science signaling. 2014; 7:ra107.
144. Faber AC, Coffee EM, Costa C, Dastur A, Ebi H, Hata AN, Yeo AT, Edelman EJ, Song Y, Tam AT, Boisvert JL, Milano RJ, Roper J, Kodack DP, Jain RK, Corcoran RB, et al. mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer discovery. 2014; 4:42-52.
145. Samalin E, Bouche O, Thezenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T, Galais MP, Assenat E, Crapez E, Poujol S, Bibeau F, Boissiere F, et al. Sorafenib and irinotecan (NEXIRI) as second-or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. British journal of cancer. 2014; 110:1148-1154.
146. Cercek A, Shia J, Gollub M, Chou JF, Capanu M, Raasch P, Reidy-Lagunes D, Proia DA, Vakiani E, Solit DB and Saltz LB. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer. Clinical colorectal cancer. 2014; 13:207-212.
147. E J, Xing J, Gong H, He J and Zhang W. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. Tumour biology. 2015; 36:1091-1097.
148. Petrelli F, Coinu A, Cabiddu M, Ghilardi M and Barni S. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Medical oncology. 2013; 30:650.
149. Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C and Ricevuto E. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? Critical reviews in oncology/hematology. 2015; 93:190-202.
150. Janku F, Wheler JJ, Hong DS and Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Targeted oncology. 2013; 8:183-188.
151. Kubackova K, Bortlicek Z, Pikus T, Linke Z, Pokorna P, Vyzula R and Prausova J. Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data. Future oncology. 2015; 11:225-232.
152. Yarden Y and Sliwkowski MX. Untangling the ErbB signalling network. Nature reviews Molecular cell biology. 2001; 2:127-137.
153. Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D and Zhang XF. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent progress in hormone research. 2001; 56:127-155.
154. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D. BRAF mutation in papillary thyroid carcinoma. Journal of the National Cancer Institute. 2003; 95:625-627.
155. Bishehsari F, Mahdavinia M, Malekzadeh R, Verginelli F, Catalano T, Sotoudeh M, Bazan V, Agnese V, Esposito DL, De Lellis L, Semeraro D, Colucci G, Hormazdi M, Rakhshani N, Cama A, Piantelli M, et al. Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Annals of oncology. 2006; 17 Suppl 7:vii91-96.
156. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-954.
157. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, Lievre A, Cortet M, Bouvier AM, Rat P, Roignot P, Faivre J, Laurent-Puig P and Piard F. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. International journal of cancer Journal international du cancer. 2008; 122:2255-2259.
158. Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M and Tejpar S. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Annals of oncology. 2014; 25:1995-2001.
159. Barras D. BRAF Mutation in Colorectal Cancer: An Update. Biomarkers in cancer. 2015; 7:9-12.
160. Magudia K, Lahoz A and Hall A. K-Ras and B-Raf oncogenes inhibit colon epithelial polarity establishment through up-regulation of c-myc. The Journal of cell biology. 2012; 198:185-194.
161. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK and Slattery ML. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer research. 2005; 65:6063-6069.
162. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B and Velculescu VE. Tumorigenesis: RAF/ RAS oncogenes and mismatch-repair status. Nature. 2002; 418:934.
163. Oikonomou E, Makrodouli E, Evagelidou M, Joyce T, Probert L and Pintzas A. BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia. 2009; 11:1116-1131.
164. Oikonomou E, Koustas E, Goulielmaki M and Pintzas A. BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget. 2014; 5:11752-11777. doi: 10.18632/oncotarget.2555.
165. Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A and Li G. The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and metaanalysis. PloS one. 2012; 7:e47054.
166. Pietrantonio F, Petrelli F, Coinu A, Di Bartolomeo M, Borgonovo K, Maggi C, Cabiddu M, Iacovelli R, Bossi I, Lonati V, Ghilardi M, de Braud F and Barni S. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. European journal of cancer. 2015; 51:587-594.
167. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS and Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. British journal of cancer. 2015; 112:1888-1894.
168. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A and Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483:100-103.
169. Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA, Settleman J, Mino-Kenudson M and Engelman JA. EGFR-mediated reactivation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer discovery. 2012; 2:227-235.
170. Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Jr., Bahl S, Anderka K, Green LM, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer discovery. 2015; 5:358-367.
171. Cremolini C, Di Bartolomeo M, Amatu A, Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile G, Lonardi S, Sartore-Bianchi A, Fontanini G, Milione M, Lauricella C, Siena S, Falcone A, et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Annals of oncology. 2015.
172. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. The New England journal of medicine. 2012; 367:1596-1606.
173. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P, Cantley LC, Giovannucci EL and Fuchs CS. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. Journal of clinical oncology. 2009; 27:1477-1484.
174. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS and Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia. 2008; 10:534-541.
175. Hsieh LL, Er TK, Chen CC, Hsieh JS, Chang JG and Liu TC. Characteristics and prevalence of KRAS, BRAF, and PIK3CA mutations in colorectal cancer by high-resolution melting analysis in Taiwanese population. Clinica chimica acta. 2012; 413:1605-1611.
176. Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, Fu S, Luthra R, Garrido-Laguna I and Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PloS one. 2011; 6:e22769.
177. Rosty C, Young JP, Walsh MD, Clendenning M, Sanderson K, Walters RJ, Parry S, Jenkins MA, Win AK, Southey MC, Hopper JL, Giles GG, Williamson EJ, English DR and Buchanan DD. PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. PloS one. 2013; 8:e65479.
178. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B and Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554.
179. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, Li S, Tsui C, Tie J, Desai J, Xu ZZ, Molloy P, Whitehall V, Leggett BA, Jones IT, McLaughlin S, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clinical cancer research. 2013; 19:3285-3296.
180. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR, Nishihara R, Meyerhardt JA, Fuchs CS and Ogino S. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clinical cancer research. 2012; 18:2257-2268.
181. Mao C, Yang ZY, Hu XF, Chen Q and Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and metaanalysis. Annals of oncology. 2012; 23:1518-1525.
182. Farina Sarasqueta A, Zeestraten EC, van Wezel T, van Lijnschoten G, van Eijk R, Dekker JW, Kuppen PJ, Goossens-Beumer IJ, Lemmens VE, van de Velde CJ, Rutten HJ, Morreau H and van den Brule AJ. PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cellular oncology. 2011; 34:523-531.
183. Cathomas G. PIK3CA in Colorectal Cancer. Frontiers in oncology. 2014; 4:35.
184. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, Davidson B, Kerr DJ, Tomlinson IP and Midgley R. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal antiinflammatory drug therapy in colorectal cancer. Journal of clinical oncology. 2013; 31:4297-4305.
185. Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J and DeCensi A. PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. Clinical oncology. 2016; 28:317-326.
186. Chan AT, Ogino S and Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. Jama. 2009; 302:649-658.
187. Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, Xia D, Yang J, Cai J and Wu Y. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015; 64:1419-1425.
188. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Seminars in thrombosis and hemostasis. 1997; 23:349-356.
189. Roth GJ and Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. The Journal of clinical investigation. 1975; 56:624-632.
190. Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS and Chan AT. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology. Oncogene. 2014; 33:2949-2955.
191. Banu SK, Lee J, Speights VO, Jr., Starzinski-Powitz A and Arosh JA. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 induces apoptosis of human endometriotic cells through suppression of ERK1/2, AKT, NFkappaB, and beta-catenin pathways and activation of intrinsic apoptotic mechanisms. Molecular endocrinology. 2009; 23:1291-1305.
192. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life sciences. 2003; 74:143-153.
193. De Keijzer S, Meddens MB, Torensma R and Cambi A. The multiple faces of prostaglandin E2 G-protein coupled receptor signaling during the dendritic cell life cycle. International journal of molecular sciences. 2013; 14:6542-6555.
194. Chang J, Vacher J, Yao B, Fan X, Zhang B, Harris RC and Zhang MZ. Prostaglandin E receptor 4 (EP4) promotes colonic tumorigenesis. Oncotarget. 2015; 6:33500-33511. doi: 10.18632/oncotarget.5589.
195. Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H and Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS letters. 2002; 518:154-158.
196. Castellone MD, Teramoto H, Williams BO, Druey KM and Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science. 2005; 310:1504-1510.
197. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM and DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103:1492-1497.
198. Wang D, Xia D and Dubois RN. The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer. Cancers. 2011; 3:3894-3908.
199. Zhang Y and Daaka Y. PGE2 promotes angiogenesis through EP4 and PKA Cgamma pathway. Blood. 2011; 118:5355-5364.
200. Bergman M, Djaldetti M, Salman H and Bessler H. Inflammation and colorectal cancer: does aspirin affect the interaction between cancer and immune cells? Inflammation. 2011; 34:22-28.
201. Wang K and Karin M. Tumor-Elicited Inflammation and Colorectal Cancer. Advances in cancer research. 2015; 128:173-196.
202. Vogel LK, Saebo M, Hoyer H, Kopp TI, Vogel U, Godiksen S, Frenzel FB, Hamfjord J, Bowitz-Lothe IM, Johnson E, Kure EH and Andersen V. Intestinal PTGS2 mRNA levels, PTGS2 gene polymorphisms, and colorectal carcinogenesis. PloS one. 2014; 9:e105254.
203. Guillem-Llobat P, Dovizio M, Bruno A, Ricciotti E, Cufino V, Sacco A, Grande R, Alberti S, Arena V, Cirillo M, Patrono C, FitzGerald GA, Steinhilber D, Sgambato A and Patrignani P. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget. 2016; doi: 10.18632/ oncotarget.8655.
204. Nieswandt B, Hafner M, Echtenacher B and Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer research. 1999; 59:1295-1300.
205. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M and Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005; 105:178-185.
206. Gay LJ and Felding-Habermann B. Contribution of platelets to tumour metastasis. Nature reviews Cancer. 2011; 11:123-134.
207. Degen JL and Palumbo JS. Hemostatic factors, innate immunity and malignancy. Thrombosis research. 2012; 129 Suppl 1:S1-5.
208. Labelle M and Hynes RO. The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination. Cancer discovery. 2012; 2:1091-1099.
209. Liao D, Zhong L, Duan T, Zhang RH, Wang X, Wang G, Hu K, Lv X and Kang T. Aspirin Suppresses the Growth and Metastasis of Osteosarcoma through the NF-kappaB Pathway. Clinical cancer research. 2015; 21:5349-5359.
210. Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ and Tang ZY. Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma. PloS one. 2013; 8:e65023.
211. Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L and Rao CV. Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer research. 2006; 66:4542-4546.
212. Miliani de Marval PL and Zhang Y. The RP-Mdm2-p53 pathway and tumorigenesis. Oncotarget. 2011; 2:234-238. doi: 10.18632/oncotarget.228.
213. Pei D, Zhang Y and Zheng J. Regulation of TP53: a collaboration between Mdm2 and Mdmx. Oncotarget. 2012; 3:228-235. doi: 10.18632/oncotarget.443.
214. Li XL, Zhou J, Chen ZR and Chng WJ. TP53 mutations in colorectal cancer-molecular pathogenesis and pharmacological reactivation. World journal of gastroenterology. 2015; 21:84-93.
215. Krasnov GS, Dmitriev AA, Lakunina VA, Kirpiy AA and Kudryavtseva AV. Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy. Expert opinion on therapeutic targets. 2013; 17:1221-1233.
216. Shoshan-Barmatz V and Mizrachi D. VDAC1: from structure to cancer therapy. Frontiers in oncology. 2012; 2:164.
217. Ryan KM, Phillips AC and Vousden KH. Regulation and function of the TP53 tumor suppressor protein. Current opinion in cell biology. 2001; 13:332-337.
218. Wang X, Simpson ER and Brown KA. TP53: Protection against Tumor Growth beyond Effects on Cell Cycle and Apoptosis. Cancer research. 2015; 75:5001-5007.
219. Ladelfa MF, Toledo MF, Laiseca JE and Monte M. Interaction of TP53 with tumor suppressive and oncogenic signaling pathways to control cellular reactive oxygen species production. Antioxidants & redox signaling. 2011; 15:1749-1761.
220. Liu J, Zhang C, Hu W and Feng Z. Tumor suppressor TP53 and its mutants in cancer metabolism. Cancer letters. 2015; 356:197-203.
221. Yeung SJ, Pan J and Lee MH. Roles of TP53, MYC and HIF-1 in regulating glycolysis-the seventh hallmark of cancer. Cellular and molecular life sciences: CMLS. 2008; 65:3981-3999.
222. Nakamura Y. Isolation of TP53-target genes and their functional analysis. Cancer science. 2004; 95:7-11.
223. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB and Cho KR. TP53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proceedings of the National Academy of Sciences of the United States of America. 1994; 91:5320-5324.
224. Krasnov GS, Dmitriev AA, Snezhkina AV and Kudryavtseva AV. Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target. Expert opinion on therapeutic targets. 2013; 17:681-693.
225. Mathupala SP, Heese C and Pedersen PL. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor TP53. The Journal of biological chemistry. 1997; 272:22776-22780.
226. Blandino G, Levine AJ and Oren M. Mutant TP53 gain of function: differential effects of different TP53 mutants on resistance of cultured cells to chemotherapy. Oncogene. 1999; 18:477-485.
227. Li R, Sutphin PD, Schwartz D, Matas D, Almog N, Wolkowicz R, Goldfinger N, Pei H, Prokocimer M and Rotter V. Mutant TP53 protein expression interferes with TP53-independent apoptotic pathways. Oncogene. 1998; 16:3269-3277.
228. Almazov VP, Kochetkov DV and Chumakov PM. Use of TP53 for therapy of human cancer. Mol Biol+. 2007; 41:863-877.
229. Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, Sekiyama A, Yoshihara M, Matsukuma S, Sakuma Y, Tsuchiya E, Kameda Y, Akaike M and Miyagi Y. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC cancer. 2009; 9:420.
230. Offer SM, Wegner NJ, Fossum C, Wang K and Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer research. 2013; 73:1958-1968.
231. Li Q, Liu Y, Zhang HM, Huang YP, Wang TY, Li DS and Sun HZ. Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis. Gastroenterology research and practice. 2014; 2014:827989.
232. Yen JL and McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? European journal of cancer. 2007; 43:1011-1016.
233. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB and Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clinical pharmacology and therapeutics. 2013; 94:640-645.
234. Rosmarin D, Palles C, Pagnamenta A, Kaur K, Pita G, Martin M, Domingo E, Jones A, Howarth K, Freeman-Mills L, Johnstone E, Wang H, Love S, Scudder C, Julier P, Fernandez-Rozadilla C, et al. A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS. Gut. 2015; 64:111-120.
235. Falvella FS, Caporale M, Cheli S, Martinetti A, Berenato R, Maggi C, Niger M, Ricchini F, Bossi I, Di Bartolomeo M, Sottotetti E, Bernardi FF, de Braud F, Clementi E and Pietrantonio F. Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase. International journal of molecular sciences. 2015; 16:8884-8895.
236. Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH and Punt CJ. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. European journal of cancer. 2009; 45:1999-2006.
237. Sasaki S, Watanabe T and Nakayama H. Analysis of the mRNA expression of chemotherapy-related genes in colorectal carcinoma using the danenberg tumor profile method. Journal of oncology. 2013; 2013:386906.
238. Farrugia DC, Ford HE, Cunningham D, Danenberg KD, Danenberg PV, Brabender J, McVicar AD, Aherne GW, Hardcastle A, McCarthy K and Jackman AL. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clinical cancer research. 2003; 9:792-801.
239. Vallbohmer D, Yang DY, Kuramochi H, Shimizu D, Danenberg KD, Lindebjerg J, Nielsen JN, Jakobsen A and Danenberg PV. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. International journal of oncology. 2007; 31:413-418.
240. Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP, Liu BR, Xu GX, Dong XL and Qian XP. UGT1A1*6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer chemotherapy and pharmacology. 2014; 73:551-560.
241. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL and Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. The pharmacogenomics journal. 2002; 2:43-47.
242. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007; 50:113-130.
243. Fearon ER and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61:759-767.
244. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S and Vogelstein B. TP53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer research. 1990; 50:7717-7722.
245. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339:1546-1558.
246. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G and Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112:118-123.
247. Sveen A, Agesen TH, Nesbakken A, Rognum TO, Lothe RA and Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome medicine. 2011; 3:32.
248. Sveen A, Johannessen B, Teixeira MR, Lothe RA and Skotheim RI. Transcriptome instability as a molecular pancancer characteristic of carcinomas. BMC genomics. 2014; 15:672.